SAN
MATEO, Calif., Sept. 5,
2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH),
("Talphera"), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for use
in medically supervised settings, today announced that management
will participate in the H.C. Wainwright 26th Annual
Global Investment Conference and will be taking 1x1 meetings.
The conference is being held on September
9-11, 2024, at the Lotte New York Palace Hotel in
New York City, and the
presentation will be available on-demand starting on Monday, September 9 at 7:00 AM ET here or by visiting the Investors
section of the Company's website at www.talphera.com and clicking
on the webcast link posted within Investors/News &
Events/Upcoming Events section.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for
use in medically supervised settings. Talphera's lead product
candidate, Niyad™ is a lyophilized formulation of nafamostat and is
currently being studied under an investigational device exemption
(IDE) as an anticoagulant for the extracorporeal circuit, and has
received Breakthrough Device Designation status from the U.S. Food
and Drug Administration (FDA).
This release is intended for investors only. For additional
information about Talphera, please visit www.talphera.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302239931.html
SOURCE Talphera, Inc.